Rontalizumab

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Rontalizumab
Monoclonal antibody
Type Whole antibody
Source Humanized
Target IFN-α
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
Formula C6486H9990N1722O2026S44
Molar mass 145.9 kg/mol
 NYesY (what is this?)  (verify)

Rontalizumab is a humanized monoclonal antibody[1] being developed by Genentech.[2] As of November 2009, it is being investigated in a clinical trial for the treatment of systemic lupus erythematosus.[3]

References[edit]

  1. ^ WHO Drug Information
  2. ^ Genentech: Rontalizumab (rhuMAb IFN alpha)
  3. ^ Clinical trial number NCT00962832 for "A Study to Evaluate the Efficacy and Safety of Rontalizumab in Patients With Moderately to Severely Active Systemic Lupus Erythematosus (ROSE)" at ClinicalTrials.gov